NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a definitive agreement with investors for the purchase of an aggregate of $6 million in securities in concurrent private placement and registered direct offerings.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.